Andre Fischer, Kwangsik Nho, Andrew J. Saykin, Ivana Delalle
{"title":"Anthony S. Zannas对“循环小rna揭示痴呆风险”这封信的回应","authors":"Andre Fischer, Kwangsik Nho, Andrew J. Saykin, Ivana Delalle","doi":"10.1002/alz.14404","DOIUrl":null,"url":null,"abstract":"<p>Dear Editor,</p><p>We are truly grateful for the positive and thoughtful feedback on our recent studies exploring microRNAs (miRNAs) as biomarkers for Alzheimer's disease (AD).<span><sup>1</sup></span> It is encouraging to see our work recognized for its potential contribution to the field of AD research.</p><p>We fully agree that replication is crucial. Although our findings highlight promising miRNA signatures, validating these results in independent cohorts will be key to solidifying their potential clinical relevance. We are confident that future studies will build upon these insights, further advancing the development of reliable biomarkers for early diagnosis and progression tracking. In addition, we would like to highlight the potential of miRNAs in identifying the different molecular and cellular phases of AD pathogenesis.</p><p>We also appreciate the remarks on the clinical utility of miRNA measurements. As the field evolves, demonstrating the added value of miRNAs alongside established biomarkers remains a priority. We are optimistic that ongoing and future research will help establish miRNAs as complementary tools for improving diagnostic precision.</p><p>The notion of miRNA-based therapies is particularly exciting. Although this was not the primary focus of our current studies, we agree that stratified RNA therapies hold immense promise as future therapeutic strategies. In AD research, it will be key to treat the right patient at the right time with the right therapeutic approach. The ability to modify miRNA levels in a targeted manner opens new avenues for addressing the different pathological phases in AD, and we look forward to contributing to this research.</p><p>In conclusion, we are delighted by the recognition of our work and are eager to continue exploring these important questions as the field progresses. We sincerely appreciate the constructive dialogue and look forward to further advancing this exciting area of research.</p><p>A. Fisher, K. Nho, A.J. Saykin, and I. Delalle</p><p>The authors declare no conflicts of interest.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14404","citationCount":"0","resultStr":"{\"title\":\"Response to the Letter, “Circulating small RNAs shed light on dementia risk,” by Anthony S. Zannas\",\"authors\":\"Andre Fischer, Kwangsik Nho, Andrew J. Saykin, Ivana Delalle\",\"doi\":\"10.1002/alz.14404\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Dear Editor,</p><p>We are truly grateful for the positive and thoughtful feedback on our recent studies exploring microRNAs (miRNAs) as biomarkers for Alzheimer's disease (AD).<span><sup>1</sup></span> It is encouraging to see our work recognized for its potential contribution to the field of AD research.</p><p>We fully agree that replication is crucial. Although our findings highlight promising miRNA signatures, validating these results in independent cohorts will be key to solidifying their potential clinical relevance. We are confident that future studies will build upon these insights, further advancing the development of reliable biomarkers for early diagnosis and progression tracking. In addition, we would like to highlight the potential of miRNAs in identifying the different molecular and cellular phases of AD pathogenesis.</p><p>We also appreciate the remarks on the clinical utility of miRNA measurements. As the field evolves, demonstrating the added value of miRNAs alongside established biomarkers remains a priority. We are optimistic that ongoing and future research will help establish miRNAs as complementary tools for improving diagnostic precision.</p><p>The notion of miRNA-based therapies is particularly exciting. Although this was not the primary focus of our current studies, we agree that stratified RNA therapies hold immense promise as future therapeutic strategies. In AD research, it will be key to treat the right patient at the right time with the right therapeutic approach. The ability to modify miRNA levels in a targeted manner opens new avenues for addressing the different pathological phases in AD, and we look forward to contributing to this research.</p><p>In conclusion, we are delighted by the recognition of our work and are eager to continue exploring these important questions as the field progresses. We sincerely appreciate the constructive dialogue and look forward to further advancing this exciting area of research.</p><p>A. Fisher, K. Nho, A.J. Saykin, and I. Delalle</p><p>The authors declare no conflicts of interest.</p>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 2\",\"pages\":\"\"},\"PeriodicalIF\":11.1000,\"publicationDate\":\"2025-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14404\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14404\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14404","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
尊敬的编辑，我们非常感谢您对我们最近探索microRNAs （miRNAs）作为阿尔茨海默病（AD）生物标志物的研究给予的积极和周到的反馈令人鼓舞的是，我们的工作因其对阿尔茨海默病研究领域的潜在贡献而得到认可。我们完全同意复制是至关重要的。尽管我们的研究结果强调了有希望的miRNA特征，但在独立队列中验证这些结果将是巩固其潜在临床相关性的关键。我们相信，未来的研究将建立在这些见解的基础上，进一步推动可靠的生物标志物的发展，用于早期诊断和进展跟踪。此外，我们想强调mirna在识别AD发病机制的不同分子和细胞阶段的潜力。我们也感谢关于miRNA测量的临床应用的评论。随着该领域的发展，证明mirna与已建立的生物标志物的附加价值仍然是一个优先事项。我们乐观地认为，正在进行的和未来的研究将有助于建立mirna作为提高诊断精度的补充工具。基于mirna的疗法的概念尤其令人兴奋。虽然这不是我们当前研究的主要焦点，但我们一致认为分层RNA疗法作为未来的治疗策略具有巨大的前景。在阿尔茨海默病的研究中，在正确的时间用正确的治疗方法治疗正确的患者将是关键。有针对性地修改miRNA水平的能力为解决AD的不同病理阶段开辟了新的途径，我们期待着为这项研究做出贡献。总之，我们很高兴我们的工作得到认可，并渴望随着该领域的进展继续探索这些重要问题。我们真诚地感谢这次建设性的对话，并期待着进一步推进这一激动人心的研究领域。Fisher， K. Nho， A.J. Saykin和I. Delalle
Response to the Letter, “Circulating small RNAs shed light on dementia risk,” by Anthony S. Zannas
Dear Editor,
We are truly grateful for the positive and thoughtful feedback on our recent studies exploring microRNAs (miRNAs) as biomarkers for Alzheimer's disease (AD).1 It is encouraging to see our work recognized for its potential contribution to the field of AD research.
We fully agree that replication is crucial. Although our findings highlight promising miRNA signatures, validating these results in independent cohorts will be key to solidifying their potential clinical relevance. We are confident that future studies will build upon these insights, further advancing the development of reliable biomarkers for early diagnosis and progression tracking. In addition, we would like to highlight the potential of miRNAs in identifying the different molecular and cellular phases of AD pathogenesis.
We also appreciate the remarks on the clinical utility of miRNA measurements. As the field evolves, demonstrating the added value of miRNAs alongside established biomarkers remains a priority. We are optimistic that ongoing and future research will help establish miRNAs as complementary tools for improving diagnostic precision.
The notion of miRNA-based therapies is particularly exciting. Although this was not the primary focus of our current studies, we agree that stratified RNA therapies hold immense promise as future therapeutic strategies. In AD research, it will be key to treat the right patient at the right time with the right therapeutic approach. The ability to modify miRNA levels in a targeted manner opens new avenues for addressing the different pathological phases in AD, and we look forward to contributing to this research.
In conclusion, we are delighted by the recognition of our work and are eager to continue exploring these important questions as the field progresses. We sincerely appreciate the constructive dialogue and look forward to further advancing this exciting area of research.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
